Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study
Tsuyoshi Sasaki,1,2 Kenji Hashimoto,3 Masumi Tachibana,1 Tsutomu Kurata,1 Keiko Okawada,1 Maki Ishikawa,1 Hiroshi Kimura,2 Hideki Komatsu,2 Masatomo Ishikawa,2 Tadashi Hasegawa,2 Akihiro Shiina,1 Tasuku Hashimoto,2 Nobuhisa Kanahara,3 Tetsuya Shiraishi,2 Masaomi Iyo1–31Department of Child...
Main Authors: | Sasaki T, Hashimoto K, Tachibana M, Kurata T, Okawada K, Ishikawa M, Kimura H, Komatsu H, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-01-01
|
Series: | Neuropsychiatric Disease and Treatment |
Online Access: | http://www.dovepress.com/tipepidine-in-children-with-attention-deficithyperactivity-disorder-a--a15629 |
Similar Items
-
Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study
by: Sasaki T, et al.
Published: (2014-05-01) -
Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study
by: Hashimoto T, et al.
Published: (2015-12-01) -
Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder
by: Takuya Saito, et al.
Published: (2020-11-01) -
Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia
by: Oda Y, et al.
Published: (2015-07-01) -
Correction: Decreased Serum Levels of Mature Brain-Derived Neurotrophic Factor (BDNF), but Not Its Precursor proBDNF, in Patients with Major Depressive Disorder
by: Taisuke Yoshida, et al.
Published: (2013-01-01)